Weekly Funding Opportunities

[Med Research]

Michael J. Fox Foundation: Analysis of Patient Reported Outcomes from Fox Insight Study<https://urldefense.com/v3/__https://www.michaeljfox.org/grant/analysis-patient-reported-outcomes-fox-insight__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65KQVjeHg$ >
PROs collected in Fox Insight capture information on the lives experience of Parkinson’s that can transform therapeutic development, clinical care and public policy for people with the disease. Data from tens of thousands of people with and without Parkinson’s participating in the study provides the necessary power to generate new understanding of a heterogeneous disease. Investigators unfamiliar with Parkinson’s who present compelling proposals for methods may be paired with a Parkinson’s expert for contextualizing analysis to clinical practice. The dataset and additional resources are available in the Fox Insight Data Exploration Network (Fox DEN)<https://urldefense.com/v3/__https://foxden.michaeljfox.org/insight/explore/insight.jsp__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65AA15pqE$ >. Competitive applications will focus on studies that achieve one or more of the following goals:

  *   Characterize disease progression for people with Parkinson’s
  *   Evaluate the utility of different instruments and/or instrument sub-items in measuring burden of disease, especially in individuals within the first two (2) years of Parkinson’s diagnosis
  *   Identify the role of pharmacological, medical device and/or non-medical interventions on managing Parkinson’s symptoms and long-term health outcomes
  *   Predict the future health status of participants without Parkinson’s based on disease risk variables and model their likelihood of developing Parkinson’s
  *   Determine elements of disease experience that drive patient preference and risk tolerance
  *   Explore the factors that affect volunteer compliance and completeness of participation in an online study
  *   Determine how economic factors, patient-physician communication and lifestyle factors influence medical treatment and long-term health outcomes in people with Parkinson’s
  *   Analyst’s choice: Researchers can submit their own analysis topics based on available Fox Insight data especially as it relates to longitudinal analyses
Pre-proposals due October 22, 2020. Med-RA deadline to receive draft documents: October 12.

Michael J. Fox Foundation: Development and Validation of Improved Outcome Measures for Parkinson’s Disease<https://urldefense.com/v3/__https://www.michaeljfox.org/grant/development-and-validation-improved-outcome-measures__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65maefSBo$ >
The Michael J. Fox Foundation invites applications for grants to fund the development of objective biomarkers that can support therapeutic development in Parkinson’s disease. Through the Development and Validation of Improved Outcome Measures  grant program, the foundation funds the development of biomarkers that enable researchers to improve definite diagnosis, objectively track disease progression, enrich for subject populations, or more precisely detect a treatment response or target engagement — biomarkers that would transform clinical trial design and assist in the interpretation of trial results.
To that end, the foundation welcomes proposals for studies that develop or validate promising biomarkers of Parkinson’s disease, prodromal biomarkers, biomarkers of phenoconversion, or specific molecular biomarker assays; analyze and derive candidate biomarkers from existing biological datasets; or develop and support remote assessment strategies that could complement in clinic assessments. Grants of up to $750,000 over up to two years will be awarded.
Pre-proposals due October 22, 2020. Med-RA deadline to receive draft documents: October 12.

PIPETTE Consortium: 4R Tau and Alpha-Synuclein PET Tracer Development<https://urldefense.com/v3/__https://www.michaeljfox.org/grant/pipette-4r-tau-and-alpha-synuclein-pet-tracer-development__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65vJ3evzE$ >
The PIPETTE Consortium (Philanthropic Investments in PET TracErs) is a funding partnership formed in 2017 by the Michael J. Fox Foundation and Rainwater Charitable Foundation (conveners of the Tau Consortium). The partnership’s goal is to accelerate the development of novel 4R tau and alpha-synuclein PET tracers for primary non-Alzheimer’s tauopathies, Parkinson’s disease, Lewy body dementia, frontotemporal dementia, and other neurodegenerative diseases. As a collaborative effort of leading non-profit organizations, the PIPETTE Consortium seeks to pool ideas, expertise, and resources to enable improved diagnosis and treatment of multiple disorders.
Applications should focus on studies that achieve one or more of the following:

  *   In vivo imaging of brain neurofilaments of 4R tau and alpha-synuclein pathology that could be useful as biomarkers of the presence of disease and disease progression and as pharmacodynamic tools for drug development for tauopathies or synucleinopathies
  *   Structure- and ligand-based drug design approaches that use state-of-art computational methods such as the high resolution Cryo-EM structures of disease-relevant tau and alpha-synuclein fibrils and existing Structure Activity Relationship (SAR) on known tau PET ligands or alpha-synuclein PET ligands that are in development
We are especially interested in projects to develop alpha-synuclein and tau tracers in parallel.
Total amount available to fund 1-2 year projects, 15% IDC: $1M.
Pre-proposals due October 22, 2020. Med-RA deadline to receive draft documents: October 12.

Michael J. Fox Foundation: Target Advancement Program<https://urldefense.com/v3/__https://www.michaeljfox.org/grant/target-advancement-program-0__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65q0XsKnw$ >
MJFF believes that promoting target and pathway validation studies within academic and industry laboratories can bridge the critical gap between basic biology and therapeutic development. Validation efforts should focus on early-stage targets that have previously been implicated in Parkinson’s but have not yet been rigorously tested for their ability to impact disease-relevant outcomes in Parkinson’s model systems. Submitted projects should investigate whether genetic or pharmacological modulation of the target can affect Parkinson’s-relevant biological pathways or phenotypes in model systems that may be predictive of therapeutic efficacy. Applications should focus on studies that achieve one or more of the following goals:

  *   Demonstrate pathological relevance of a target by studying its altered expression, distribution, or function in Parkinson’s-relevant human tissues.
  *   Demonstrate that modulation of the target or pathway in vivo in whole mammalian Parkinson’s models using genetic or pharmacological manipulations yields outcomes predictive of clinical efficacy or relevance in human Parkinson’s disease.
  *   Elucidate target or pathway biology in disease-relevant models, including defining upstream/downstream modifiers and convergence of promising target pathways.
Pre-proposals due October 22, 2020. Med-RA deadline to receive draft documents: October 12.

Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3 / UH3 Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-030.html__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65UyHqtC0$ >
This Funding Opportunity Announcement invites researchers to submit applications for multidisciplinary diagnostic strategies for rare diseases that combine machine-assistance, genomic analysis, and clinical consultation. Of particular importance, these strategies must be able to be adopted and performed at the primary or secondary care levels by front-line healthcare providers and be readily integrated into their clinical care workflow.
Due November 12, 2020. Med-RA deadline to receive draft documents: October 29.

U.S. Tobacco Control Policies to Reduce Health Disparities (R21 / R01 Clinical Trial Optional)
R21<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/par-20-303.html__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic657HsqxHQ$ >
R01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-302.html__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic658QP0sss$ >
The purpose of these Funding Opportunity Announcements (FOAs) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, these FOAs aim to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of these FOAs is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations.
Due November 12, 2020, and on standard dates thereafter. Expires September 8, 2023. Med-RA deadline to receive draft documents for November 12 due date: October 29.

New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 / R34)
R01 (Clinical Trial Required)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-273.html__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65m4CWmQI$ >
R34 (Clinical Trial Optional)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-274.html__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic659gUVSuw$ >
The purpose of these FOAs is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services. NIDA is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV and SUD in the US.
Due November 18, 2020; August 11, 2021; November 18, 2021; August 11, 2022; November 18, 2022; and August 11, 2023. Med-RA deadline to receive draft documents for November 18 due date: November 5.

NIH Blueprint for Neuroscience Research: Functional Neural Circuits of Interoception (R01, Clinical Trial Not Allowed)<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-21-003.html__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65e3aAfbQ$ >
The goal of this FOA is to enhance our fundamental understanding of interoception with a specific focus on dissecting and determining the function of neural circuits that connects peripheral organs/tissues with the central nervous system (CNS) via peripheral ganglia. For this FOA, interoception science includes studies of the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself. This FOA encourages projects that combine diverse expertise and use innovative approaches to delineate interoceptive mechanisms at the molecular, cellular, circuitry, functional, and/or behavioral levels. Outcomes of this research will lay a critical foundation for future translational and clinical research on interoception as well as its roles in nervous system disorders.
Due December 18, 2020. Med-RA deadline to receive draft documents for November 18 due date: December 7.

NCI Research Specialist Awards: Core-based Scientist and Laboratory-based Scientist (R50 Clinical Trial Not Allowed)
These Funding Opportunity Announcements (FOAs) invite grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research.
R50 Core-based Scientist<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-287.html__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65JrwqYqc$ >
This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.
R50 Laboratory-based Scientist<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-288.html__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65vm2c0P4$ >
This FOA is specifically for laboratory-based scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award.
Due January 4, 2021. Med-RA deadline to receive draft documents for November 18 due date: December 14.

HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed) <https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-21-024.html__;!!PhOWcWs!ldMkgGWhE8FwiVOi55zJSklFLQTtZKhF0xmdERpG15V5ljAV8H37I5Ml9XH0ng8w-r9ln-bYic65KV9yEjc$ >
The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included.
Due March 15, 2021; March 15, 2022; and March 15, 2023. Med-RA deadline to receive draft documents for March 15 due date: March 2.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.





-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200909/ad03ed82/attachment.html>